Goldman Sachs Asset Management (GS) is nearing a more than EUR 2B deal to buy drugmaker Synthon from BC Partners, people familiar tell the Financial Times, Ivan Levingston, Hannah Kuchler and Alexandra Heal report. BC Partners, which acquired a majority stake in the business in 2019 at an enterprise value of EUR 750M, will retain a roughly 25% stake in the group after the deal, one of the people says. TPG (TPG) and Permira were also among the bidders, the people add.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GS:
- Trump Trade: Amazon plans $1M donation to Trump’s inaugural fund
- Blackstone Reportedly Joins $3.5B Bidding War for Mitsubishi Tanabe Pharma
- Trump advisers explore pathways to shrink, eliminate bank regulators, WSJ says
- CFPB closes overdraft loophole that exempted overdraft loans from lending laws
- Goldman Sachs CFO says ‘no question’ U.S. economy has proved to be resilient